Short Summary
The suit concerns the infringement of Plaintiff No. 1's patent (IN 297581) related to the drug Osimertinib, a second-line treatment for non-small cell lung cancers. The Plaintiffs sought an ad interim injunction against the Defendants who were allegedly manufacturing and selling infringing versions under the brand OSITAB.
Detailed Summary
of the Paris Local Division of the Unified Patent Court concerning a request for extension of time filed by the Bosch defendants. The judge-rapporteur rejected Bosch's request, finding that a non-redacted version of Valeo's 15 June 2026 filing had been deposited in the CMS simultaneously with the redacted version, and that Bosch had failed to exercise due diligence in accessing it. The court ruled that the deadlines under R.29(d) RdP run from 15 June 2026.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court - Orders. Understanding the court's reasoning in Astrazeneca Ab & Anr. vs Azista Industries Pvt Ltd & Ors. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Astrazeneca AbvsEmcure Pharmaceuticals Limited
Astrazeneca sued Emcure Pharmaceuticals Limited and MSN Laboratories Limited for infringing their patents related to the pharmaceutical compound TICAGRELOR, marketed as BRILINTA. The plaintiffs sought an interim injunction against the defendants' generic versions (TICAPLAT and TIARE).
Sterlite Technologies LimitedvsZtt India Private Limited
The plaintiff sought to amend its plaint to implead ZTT International Limited as a necessary party, alleging that the entity infringes the plaintiff's patent through the import and sale of optical fibre cable. The court allowed the amendment, finding the proposed defendant was indeed a necessary party based on the facts pleaded in the written statement.
Haryana Pesticides Manufactures AssociationvsWillowood Chemicals Private Limited
The petitioner challenged an impugned order passed by the Deputy Controller of Patents and Designs, which granted a patent for 'Novel Fungicidal Composition'. The petitioner argued that the respondent made amendments to their claims without providing them an opportunity to be heard. However, the court dismissed the writ petition, holding that the petitioner had already availed of alternative remedies.
M/s.Star PlasticsvsSajeev Antony
The Madras High Court allowed the petition filed by M/s. Star Plastics seeking the cancellation and rectification of a conflicting trademark registration held by Sajeev Antony's firm. The court found that despite 'STAR' being a common term, the Petitioner had established extensive reputation and prior use of the mark in Class 11 goods long before the Respondent commenced business. Given the high likelihood of consumer confusion when viewing the marks side-by-side, the Court ruled that the Respondent's adoption was neither honest nor concurrent, leading to the cancellation of the impugned registration.
Excitel Private LimitedvsThe Registrar Of Trade Marks
The Delhi High Court overturned the rejection of the trade mark application 'REELTIME' by the Senior Examiner. The court held that website printouts could constitute valid evidence of use, provided they are accompanied by a Section 65B certificate under the IT Act. Furthermore, the court found that prior registrations and a settlement agreement with Google LLC were sufficient to establish the Appellant's rights, allowing the mark to proceed for advertisement.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.